A meta-analysis of p38 mitogen-activated protein kinase inhibitors in patients with active rheumatoid arthritis
Clinical Rheumatology 2013 doi 10.1007/s10067-013-2340-1
The role of p38-MAPK inhibitors in treating RA is the subject of some debate. Li et al. therefore performed the first meta-analysis of the current data to evaluate the efficacy and safety of these compounds. The authors identified 3 papers, covering 4 RCTs, for analysis and the results showed that p38-MAPK inhibition achieves a better level of ACR20 improvement vs. placebo, but showed no meaningful difference in ACR50, DAS28 or CRP levels past week 12. Due to the inadequate number and quality of...